The distribution of lead in human hemopoietic tissue and spongy bone after lead poisoning and Ca-EDTA chelation therapy. Observations made by atomic absorption spectroscopy, laser microbeam mass analysis and electron microbeam X-ray analysis.
Two iliac crest needle biopsies were taken from a 43-year-old lead-poisoned woman during and after completion of a Ca-EDTA treatment. By atomic absorption spectroscopy the first and second biopsy were found to contain 56, respectively 41.6 micrograms lead/g wet tissue. In both biopsies 36% of the lead was extractable in 0.1 N HCl. Electron microbeam X-ray analysis proved to have too low sensitivity for quantitation of the lead in these biopsies. Laser microbeam mass analysis (LAMMA), performed only on the second biopsy, revealed a high and fairly constant residual lead concentration in all bone marrow cell nuclei (approximately 55 micrograms/g) and a low lead concentration in the cytoplasm of the same cells (4-12 micrograms/g). The extracellular bone matrix lead was greatly concentrated in the superficial 3-6 microns osteoid zone of the bony trabeculae and totally absent from deeper parts of the mineralized matrix. The LAMMA results are in good agreement with those of subcellular fractionation experiments and atomic absorption spectroscopy, provided that the relative volume fraction of nucleus and cytoplasm is accounted for. The high residual osteoid lead after completed chelation therapy indicates that lead has a stronger affinity for the organic than the mineral components of bone matrix.
Flood
P R
PR
Institute of Anatomy, University of Bergen, Norway.
Schmidt
P F
PF
Wesenberg
G R
GR
Gadeholt
H
H
D000328:Adult; D001707:Biopsy, Needle; D001853:Bone Marrow / Q000187:drug effects / Q000378:metabolism*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism*; D002614:Chelating Agents / Q000627:therapeutic use*; D004492:Edetic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007854:Lead / Q000097:blood / Q000378:metabolism*; D007855:Lead Poisoning / Q000188:drug therapy* / Q000378:metabolism; D008099:Liver / Q000473:pathology; D010396:Penicillamine / Q000627:therapeutic use; D013054:Spectrophotometry, Atomic
D002614:Chelating Agents; D007854:Lead; D004492:Edetic Acid; D010396:Penicillamine